Amoeba Sa · EURONEXT:ALMIB
Amoeba Sa — Investor Presentation (January 2025)
22 slides from Amoeba Sa's investor presentation, January 2025
Slide 1: January 2025 | Investors Presentation
January 2025 | Investors Presentation
Slide 2: Your Contacts
Introduction YOUR CONTACTS A new dynamic driven by a united team with solid experience in international environments Benoit VILLERS Jean-François DOUCET Chairman of the Board of Directors CEO and Chief Financial Officer Since December 2023 Since May 2023 • Member of senior management at Barry • 30 y
Slide 3: A Lyon-Based Greentech
Introduction A LYON-BASED GREENTECH Listed on Euronext Growth Amoéba Created in 2010, Amoéba is a french greentech specializes in the development of natural microbiological solutions based on the patented use of amoebas. Some figures 2 1 39 1 20 Business focus: Development Patents Production unit in
Slide 4: Amoéba Chronology
Introduction AMOÉBA CHRONOLOGY From an R&D company to a Commercialization company 2010 Creation of Amoéba 13 years of R&D to become the only company in the world capable of producing amoeba on an industrial scale 2015 Initial public offering Euronext Growth 2023 Start of the transformation of an R&D
Slide 5: The Amoeba, Definition and Specific Features
Development THE AMOEBA, DEFINITION AND SPECIFIC FEATURES An amoeba Our amoeba A naturally occurring unicellular microorganism found in all Origin W. magna C2C Maky biosourced in Aix-les-Bains thermal spring environmental compartments, particularly in humid water, and secure storage environments, inc
Slide 6: A Technological Platform with Multiple Applications
Development A TECHNOLOGICAL PLATFORM WITH MULTIPLE APPLICATIONS 2 pre-marketing ranges Biocontrol Cosmetics Crop treatment Cosmetics ingredient Natural alternative to chemical plant protection Skin care and Well-Aging ingredients products INCI listing obtained worldwide Positive and definitive concl
Slide 7: Axpera
Biocontrol AXPERA Our range of solutions for the transition from chemical to organic production Positive impact on agriculture Market launch targeted for 2025 A highly competitive level of performance, Regulatory demonstrated by over 600 field trials carried out in Positive and definitive conclusion
Slide 8: The Ideal Solution
Biocontrol THE IDEAL SOLUTION To reduce the use of copper Efficacy on powdery mildew for tomatoes Context Copper is widely used to combat mildew, but its use poses environmental problems. From 2025, European regulations will continue to reduce the use of copper in agriculture. 72% efficiency Solutio
Slide 9: Positive Assessment by the EFSA
Biocontrol POSITIVE ASSESSMENT BY THE EFSA A determining milestone now completed What does the EFSA say? ✓ Proven fungicidal efficacy; ✓ A low-risk profile for human and animal health, as well as for ecosystems and environmental organisms; The European Food Safety Authority (EFSA) is one of the Euro
Slide 10: Amoeba x Koppert (1/2)
Biocontrol AMOEBA x KOPPERT (1/2) Signature of a Memorandum of understanding The start of a collaboration with Why partner together ? a world leader in biocontrol ✓ Mutual expertise: Koppert, a global leader in biocontrol, has conducted a Koppert offers "a system of specialist knowledge thorough due
Slide 11: Amoeba x Koppert (2/2)
Biocontrol AMOEBA x KOPPERT (2/2) Signature of a Memorandum of understanding A new milestone for Amoéba ✓ A MoU have been signed at the end of 2024 ✓ 5-Month Exclusive Negotiation to explore the various aspects of global cooperation: Distribution Production Regulatory Financing Co-development author
Slide 12: Skin Protection (Anti-Ageing / Anti-UV) - In-vitro tests
Cosmetics – In-vitro tests SKIN PROTECTION (ANTI-AGEING / ANTI-UV) A recent and promising innovation with proven effects October 2023 - Remarkable in-vitro studies Anti-ageing effect A restored skin structure Anti-UV effect Young skin irradiated Young skin treated and with UV then irradiated with UV
Slide 13: Skin Protection (Anti-Ageing / Anti-UV) - Clinical study
Cosmetics – Clinical study SKIN PROTECTION (ANTI-AGEING / ANTI-UV) A recent and promising innovation with proven effects May 2024 – the clinical study Wrinkle reduction after 28 days confirms excellent in-vitro tests Results of clinical trials justifying very strong claims in the field of anti-agein
Slide 14: Skin Protection (Anti-Ageing / Anti-UV)
Cosmetics SKIN PROTECTION (ANTI-AGEING / ANTI-UV) A recent and promising innovation with proven effects 2023 2024 2025 2025-26 2026-27 Brevet INCI Label Cosmos Developpement Production et Filing of a patent to Inclusion of our cosmetic approved • Business development commercialisation protect the us
Slide 15: A Company with Strong Support
Governance & Ownership A COMPAGNY WITH STRONG SUPPORT Board of Directors Shareholder structure Benoit VILLERS Chairman 30% Valérie LORENTZ-POINSOT Quentin HUA Ex-CEO Laboratoires Boiron Laboratoires Boiron 70% Patrice SELLES Jean-Luc SOUCHE Former Executive at Syngenta Ex Director at Amoéba Ex-CEO B
Slide 16: Scalable Industrial Capacities
Production SCALABLE INDUSTRIAL CAPACITIES A strategy to minimize direct investments 2024 2025-26 2026 Existing line in Chassieu. Capacity increase in 3 phases at Chassieu. Priority given to finding a production Current capacity of 0.5 tonne Gradual increase from 0.5 tonne to 10 tonnes partnership (C
Slide 17: Legal Reorganization Project
Organization LEGAL REORGANIZATION PROJECT Listed company • R&D AMOÉBA S.A. • Production • Support services Operating companies Cosmetics Biocontrol • By activity 21/01/2025 17
Slide 18: A Profitable Company from 2027
Trajectory A PROFITABLE COMPANY FROM 2027 Two complementary markets to optimise the platform's current potential and diversify risks Biocontrol Cosmetics High-volume market High-margin market EBITDA 21/01/2025 break-even by 2027 18
Slide 19: Why Invest
Investment WHY INVEST The only company dedicated to growing amoebas Unique technological expertise Leading position ✓ The only company in the world capable of growing ✓ Competitive advantages thanks to unique specialisation and amoebae on an industrial scale. expertise. ✓ Exclusive technology enabli
Slide 20: Why Invest Now?
Investment WHY INVEST NOW ? A financial market rediscovering Amoéba Share price in 2024 2015 Initial public offering (Euronext Growth) +140% Positive share price trend in 2024 47 M€ Market capitalization 161 k€ Average daily volume (since 1/10/2024) Cours de bourse d’Amoéba du 29.12.2023 au 31.12.20
Slide 21: Amoéba amoeba-nature.com amoeba@actus.fr
Amoéba amoeba-nature.com amoeba@actus.fr
Slide 22: Disclaimer
DISCLAIMER References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question-and-answer session following that oral presentation and any further information that may b